Figure 1 | British Journal of Cancer

Figure 1

From: Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)

Figure 1

(A) Risk of locoregional relapse, by treatment. Estimates shown are the absolute risk differences: combined modality therapy (CMT) minus radiotherapy (RT) alone (95% confidence interval (CI)). Number of locoregional relapses: RT alone: 151; CMT: 84 (excludes deaths and relapses within 6 weeks from the end of initial treatment). Hazard ratio (HR): 0.46 (95% CI: 0.35–0.60). (B) Relapse-free survival, by treatment. Estimates shown are the absolute risk differences: CMT minus RT alone (95% CI). Median: RT alone: 1.3 years; CMT: 4.6 years. HR: 0.70 (95% CI: 0.58–0.84).

Back to article page